Actively Recruiting
Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure
Led by Aalborg University Hospital · Updated on 2024-08-30
1616
Participants Needed
6
Research Sites
783 weeks
Total Duration
On this page
Sponsors
A
Aalborg University Hospital
Lead Sponsor
R
Rigshospitalet, Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.
CONDITIONS
Official Title
Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Heart failure patients with atrial fibrillation within the past 12 months
- Heart failure with reduced ejection fraction (HFrEF) clinically assessed
- Indication for or ongoing guideline-directed medical therapy for HFrEF
- Left ventricular ejection fraction below 50% within past 12 months
- Symptomatic atrial fibrillation documented by ECG, Holter, or cardiac device
- Asymptomatic atrial fibrillation with clinical indication for rhythm or rate control or multiple ECG-detected episodes or prolonged episodes on Holter or cardiac device
- Age between 18 and 80 years
- Receiving or planned uptitration of optimal medical therapy for HFrEF
- On anticoagulation treatment for stroke prevention according to AF guidelines
You will not qualify if you...
- Life expectancy less than 1 year
- Body mass index over 40
- Contraindications or unacceptable side effects to rate limiting drugs and amiodarone
- Left atrial size indexed for body surface area over 60 ml/m2 on recent echocardiography
- Persistent or permanent atrial fibrillation over 1 year
- Previous atrial fibrillation ablation or surgery
- Reversible causes of atrial fibrillation such as recent infection, untreated thyroid disease, or surgery
- Severe valvular heart disease
- Acute myocardial infarction, cardiothoracic surgery, or stroke within past 3 months
- Planned cardiothoracic surgery
- Listed for heart transplant
- Contraindications for anticoagulation or catheter ablation
- Severe kidney disease (chronic kidney disease stage 5 or higher)
- Pregnancy
- Unwillingness to try medical therapy for atrial fibrillation
- Unable or unwilling to give informed consent for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Aalborg University Hospital, Department of Cardiology
Aalborg, Denmark, 9000
Actively Recruiting
2
Aarhus University Hospital
Aarhus, Denmark, 8200
Not Yet Recruiting
3
Department of Cardiology, Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
4
Department of Cardiology, Herlev-Gentofte University Hospital
Hellerup, Denmark, 2900
Actively Recruiting
5
Department of Cardiology, Odense University Hospital
Odense, Denmark, 5000
Not Yet Recruiting
6
Department of Cardiology, Zealand University Hospital
Roskilde, Denmark, 4000
Not Yet Recruiting
Research Team
A
Anne-Christine Ruwald, MD, PhD
CONTACT
S
Sam Riahi, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here